[1]
Pizza V, Agresta A, D’Acunto CW, Festa M, Capasso A. Neuroinflamm-aging and neurodegenerative diseases: An overview. CNS Neurol Disord Drug Targets 2011; 10(5): 621-34.
[2]
Duncan GW. The aging brain and neurodegenerative diseases. Clin Geriatr Med 2011; 27(4): 629-44.
[3]
Morris JC. Neurodegenerative disorders of aging: The down side of rising longevity. Mo Med 2013; 110(5): 393-4.
[4]
Wolfson C, Fereshtehnejad SM, Pasquet R, Postuma R, Keezer MR. High burden of neurological disease in the older general population: Results from the Canadian longitudinal study on aging. Eur J Neurol 2019; 26(2): 356-62.
[5]
Veldurthy V, Wei R, Oz L, Dhawan P, Jeon YH, Christakos S. Vitamin D, calcium homeostasis and aging. Bone Res 2016; 4: 16041.
[6]
de Jongh RT, van Schoor NM, Lips P. Changes in vitamin D endocrinology during aging in adults. Mol Cell Endocrinol 2017; 453: 144-50.
[7]
Bivona G, Agnello L, Ciaccio M. Vitamin D and immunomodulation: Is it time to change the reference values? Ann Clin Lab Sci 2017; 47(4): 508-10.
[8]
Gonçalves de Carvalho CM, Ribeiro SM. Aging, low-grade systemic inflammation and vitamin D: A mini-review. Eur J Clin Nutr 2017; 71(4): 434-40.
[9]
Christakos S, Dhawan P, Verstuyf A. Verlinden L, Carmeliet G,. Vitamin D. Vitamin D: Metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev 2016; 96(1): 365-408.
[10]
Annweiler C. Vitamin D in dementia prevention. Ann N Y Acad Sci 2016; 1367(1): 57-63.
[11]
Kalueff AV, Minasyan A, Keisala T, Kuuslahti M, Miettinen S, Tuohimaa P. The vitamin D neuroendocrine system as a target for novel neurotropic drugs. CNS Neurol Disord Drug Targets 2006; 5(3): 363-71.
[12]
Sakuma M, Kitamura K, Endo N, et al. Low serum 25-hydroxyvitamin D increases cognitive impairment in elderly people. J Bone Miner Metab 2019; 37(2): 368-75.
[13]
Gmiąt A, Jaworska J, Micielska K, et al. Improvement of cognitive functions in response to a regular Nordic walking training in elderly women - A change dependent on the training experience. Exp Gerontol 2018; 104: 105-12.
[14]
Kubis AM, Piwowar A. The new insight on the regulatory role of the vitamin D3 in metabolic pathways characteristic for cancerogenesis and neurodegenerative diseases. Ageing Res Rev 2015; 24(Pt B): 126--37.
[15]
Song L. Calcium and bone metabolism indices. Adv Clin Chem 2017; 82: 1-46.
[16]
Ryan JW, Anderson PH, Morris HA. Pleiotropic activities of vitamin D receptors - adequate activation for multiple health outcomes. Clin Biochem Rev 2015; 36(2): 53-61.
[17]
Gilchrest BA. Sun exposure and vitamin D sufficiency. Am J Clin Nutr 2008; 88(2): 570S-7S.
[18]
Eyles DW, Feron F, Cui X, et al. Developmental vitamin D deficiency causes abnormal brain development. Psychoneuroendocrinology 2009; 34(Suppl. 1): S247-57.
[19]
Caprio M, Infante M, Calanchini M, Mammi C, Fabbri A, Vitamin D. Not just the bone. Evidence for beneficial pleiotropic extraskeletal effects. Eat Weight Disord 2017; 22(1): 27-41.
[20]
Pierrot-Deseilligny C, Souberbielle JC. Vitamin D and multiple sclerosis: An update. Mult Scler Relat Disord 2017; 14: 35-45.
[21]
Sintzel MB, Rametta M, Reder AT. Vitamin D and multiple sclerosis: A comprehensive review. Neurol Ther 2018; 7(1): 59-85.
[22]
Breuer J, Loser K, Mykicki N, Wiendl H, Schwab N. Does the environment influence multiple sclerosis pathogenesis via UVB light and/or induction of vitamin D? J Neuroimmunol 2019; 329: 1-8.
[23]
Lazic SE. Statistical evaluation of methods for quantifying gene expression by autoradiography in histological sections. BMC Neurosci 2009; 10: 5.
[24]
Stumpf WE. Whole-body and microscopic autoradiography to determine tissue distribution of biopharmaceuticals -- target discoveries with receptor micro-autoradiography engendered new concepts and therapies for vitamin D. Adv Drug Deliv Rev 2013; 65(8): 1086-97.
[25]
Kalueff AV, Minasyan A, Keisala T, Kuuslahti M, Miettinen S, Tuohimaa P. The vitamin D neuroendocrine system as a target for novel neurotropic drugs. CNS Neurol Disord Drug Targets 2006; 5(3): 363-71.
[26]
Cui X, Gooch H, Petty A, McGrath JJ, Eyles D. Vitamin D and the brain: Genomic and non-genomic actions. Mol Cell Endocrinol 2017; 453: 131-43.
[27]
Landel V, Stephan D, Cui X, Eyles D, Feron F. Differential expression of vitamin D-associated enzymes and receptors in brain cell subtypes. J Steroid Biochem Mol Biol 2018; 177: 129-34.
[28]
Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 2005; 29(1): 21-30.
[29]
Eyles DW, Liu PY, Josh P, Cui X. Intracellular distribution of the vitamin D receptor in the brain: Comparison with classic target tissues and redistribution with development. Neuroscience 2014; 268: 1-9.
[30]
Littlejohns TJ, Henley WE, Lang IA, et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology 2014; 83(10): 920-8.
[31]
McCann JC, Ames BN. Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? FASEB J 2008; 22(4): 982-1001.
[32]
Lawrence DW, Sharma B. A review of the neuroprotective role of vitamin D in traumatic brain injury with implications for supplementation post-concussion. Brain Inj 2016; 30(8): 960-8.
[33]
Santos CM. New agents promote neuroprotection in Parkinson’s disease models. CNS Neurol Disord Drug Targets 2012; 11(4): 410-8.
[34]
Orme RP, Middleditch C, Waite L, Fricker RA. The role of vitamin D3 in the development and neuroprotection of midbrain dopamine neurons. Vitam Horm 2016; 100: 273-97.
[35]
Nameni G, Hajiluian G, Shahabi P, et al. The impact of vitamin D supplementation on neurodegeneration, TNF-α concentration in hypothalamus, and CSF-to-plasma ratio of insulin in high-fat-diet-induced obese rats. J Mol Neurosci 2017; 61(2): 247-55.
[36]
Mpandzou G, Aït Ben Haddou E, Regragui W, Benomar A, Yahyaoui M. Vitamin D deficiency and its role in neurological conditions: A review. Rev Neurol (Paris) 2016; 172(2): 109-22.
[37]
Lima LAR, Lopes MJP, Costa RO, et al. Vitamin D protects dopaminergic neurons against neuroinflammation and oxidative stress in hemiparkinsonian rats. J Neuroinflammation 2018; 15(1): 249.
[38]
Langer-Gould A, Lucas RM, Xiang AH, et al. Vitamin D-binding protein polymorphisms, 25-hydroxyvitamin D, sunshine and multiple sclerosis. Nutrients 2018; 10(2): 84.
[39]
Kesselring J. Sunshine on MS. Neuroepidemiology 2008; 31(4): 280-1.
[40]
Schreuder F. Sunlight and MS. J Neurol Sci 2011; 300(1-2): 197.
[41]
Taylor BV. Sunshine and multiple sclerosis. J Neurol Neurosurg Psychiatry 2013; 84(10): 1066.
[42]
Zhu D, Liu GY, Lv Z, Wen SR, Bi S, Wang WZ. Inverse associations of outdoor activity and vitamin D intake with the risk of Parkinson’s disease. J Zhejiang Univ Sci B 2014; 15(10): 923-7.
[43]
Suzuki M, Yoshioka M, Hashimoto M, et al. Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. Am J Clin Nutr 2013; 97(5): 1004-13.
[44]
Sato Y, Honda Y, Iwamoto J. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology 2007; 68(12): 911-5.
[45]
Sato Y, Manabe S, Kuno H, Oizumi K. Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D3 in elderly patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999; 66(1): 64-8.
[46]
van den Bos F, Speelman AD, van Nimwegen M, et al. Bone mineral density and vitamin D status in Parkinson’s disease patients. J Neurol 2013; 260(3): 754-60.
[47]
Evatt ML, DeLong MR, Kumari M, Auinger P, McDermott MP, Tangpricha V. High prevalence of hypovitaminosis D status in patients with early Parkinson disease. Arch Neurol 2011; 68(3): 314-9.
[48]
Abe S, Ezaki O, Suzuki M. Medium-chain triglycerides in combination with leucine and vitamin D benefit cognition in frail elderly adults: A randomized controlled trial. J Nutr Sci Vitaminol (Tokyo) 2017; 63(2): 133-40.
[49]
Balion C, Griffith LE, Strifler L, et al. Vitamin D, cognition, and dementia: A systematic review and meta-analysis. Neurology 2012; 79(13): 1397-405.
[50]
Stein MS, Scherer SC, Ladd KS, Harrison LC. A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer’s disease. J Alzheimers Dis 2011; 26(3): 477-84.
[51]
O’Connell K, Sulaimani J, Basdeo SA, et al. Effects of vitamin D3 in clinically isolated syndrome and healthy control participants: A double-blind randomised controlled trial. Mult Scler J Exp Transl Clin 2017; 3(3)2055217317727296
[52]
Ashtari F, Toghianifar N, Zarkesh-Esfahani SH, Mansourian M. High dose vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial. Neurol Res 2016; 38(10): 888-92.
[53]
Røsjø E, Lossius A, Abdelmagid N, et al. Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosis. Mult Scler 2017; 23(3): 395-402.
[54]
Sotirchos ES, Bhargava P, Eckstein C, et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology 2016; 86(4): 382-90.
[55]
Fitzgerald KC, Munger KL, Köchert K, et al. Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta-1b. JAMA Neurol 2015; 72(12): 1458-65.
[56]
Ashtari F, Toghianifar N, Zarkesh-Esfahani SH, Mansourian M. Short-term effect of high-dose vitamin D on the level of interleukin 10 in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial. Neuroimmunomodulation 2015; 22(6): 400-4.
[57]
Toghianifar N, Ashtari F, Zarkesh-Esfahani SH, Mansourian M. Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial. J Neuroimmunol 2015; 285: 125-8.
[58]
Achiron A, Givon U, Magalashvili D, et al. Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double-blind placebo-controlled study. Mult Scler 2015; 21(6): 767-75.
[59]
Golan D, Halhal B, Glass-Marmor L, et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: A randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurol 2013; 13: 60.
[60]
Golan D, Staun-Ram E, Glass-Marmor L, et al. The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis. Brain Behav Immun 2013; 32: 180-5.
[61]
Pozuelo-Moyano B, Benito-León J, Mitchell AJ, Hernández-Gallego J. A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis. Neuroepidemiology 2013; 40(3): 147-53.
[62]
Derakhshandi H, Etemadifar M, Feizi A, et al. Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: A double blind, randomized, placebo-controlled pilot clinical trial. Acta Neurol Belg 2013; 113(3): 257-63.
[63]
James E, Dobson R, Kuhle J, Baker D, Giovannoni G, Ramagopalan SV. The effect of vitamin D-related interventions on multiple sclerosis relapses: A meta-analysis. Mult Scler 2013; 19(12): 1571-9.
[64]
Røsjø E, Steffensen LH, Jørgensen L, et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. J Neurol 2015; 262(12): 2713-21.
[65]
Rolf L, Muris AH, Mathias A, et al. Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis. Mult Scler 2018; 24(10): 1280-7.
[66]
Holmøy T, Lindstrøm JC, Eriksen EF, Steffensen LH, Kampman MT. High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurol 2017; 17(1): 67.
[67]
Hart PH, Lucas RM, Booth DR, et al. Narrowband UVB phototherapy for clinically isolated syndrome: A trial to deliver the benefits of vitamin D and other UVB-induced molecules. Front Immunol 2017; 8: 3.
[68]
Hempel S, Graham GD, Fu N, et al. A systematic review of the effects of modifiable risk factor interventions on the progression of multiple sclerosis. Mult Scler 2017; 23(4): 513-24.
[69]
Muris AH, Smolders J, Rolf L, Thewissen M, Hupperts R, Damoiseaux J. Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNβ; the SOLARIUM study. J Neuroimmunol 2016; 300: 47-56.
[70]
Salari M, Janghorbani M, Etemadifar M, Dehghani A, Razmjoo H, Naderian G. Effects of vitamin D on retinal nerve fiber layer in vitamin D deficient patients with optic neuritis: Preliminary findings of a randomized, placebo-controlled trial. J Res Med Sci 2015; 20(4): 372-8.
[71]
Etemadifar M, Janghorbani M. Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: Preliminary findings of a randomized-controlled trial. Iran J Neurol 2015; 14(2): 67-73.
[72]
Shirvani-Farsani Z, Behmanesh M, Mohammadi SM, Naser Moghadasi A. Vitamin D levels in multiple sclerosis patients: Association with TGF-β2, TGF-βRI, and TGF-βRII expression. Life Sci 2015; 134: 63-7.
[73]
Åivo J, Hänninen A, Ilonen J, Soilu-Hänninen M. Vitamin D3 administration to MS patients leads to increased serum levels of Latency Activated Peptide (LAP) of TGF-beta. J Neuroimmunol 2015; 280: 12-5.
[74]
Ascherio A, Munger KL, White R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 2014; 71(3): 306-14.
[75]
Najafipoor A, Roghanian R, Zarkesh-Esfahani SH, Bouzari M, Etemadifar M. The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients. Cell Immunol 2015; 294(1): 9-12.
[76]
Bhargava P, Fitzgerald KC, Calabresi PA, Mowry EM. Metabolic alterations in multiple sclerosis and the impact of vitamin D supplementation. JCI Insight 2017; 2(19): 95302.
[77]
Muris AH, Smolders J, Rolf L, et al. Vitamin D status does not affect disability progression of patients with multiple sclerosis over three-year follow-up. PLoS One 2016; 11(6)e0156122
[78]
Wergeland S, Myhr KM, Løken-Amsrud KI, et al. Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients. Eur J Neurol 2016; 23(6): 1064-70.
[79]
Mowry EM, Pelletier D, Gao Z, Howell MD, Zamvil SS, Waubant E. Vitamin D in clinically isolated syndrome: Evidence for possible neuroprotection. Eur J Neurol 2016; 23(2): 327-32.
[80]
Narooie-Nejad M, Moossavi M, Torkamanzehi A, Moghtaderi A. Positive association of vitamin D receptor gene variations with multiple sclerosis in South East Iranian population. BioMed Res Int 2015; 2015427519
[81]
Kubicka K, Pierzchała K. Concentration of 25(OH)D3 and calcium and phosphorus metabolism in patients suffering from relapsing-remitting multiple sclerosis. A pilot study. Neurol Neurochir Pol 2013; 47(2): 126-30.
[82]
Brum DG, Comini-Frota ER, Vasconcelos CC, Dias-Tosta E. Supplementation and therapeutic use of vitamin D in patients with multiple sclerosis: Consensus of the Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology. Arq Neuropsiquiatr 2014; 72(2): 152-6.
[83]
O’Connell K, Kelly S, Kinsella K, et al. Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: Study protocol for an exploratory randomized double- blind placebo-controlled trial. Trials 2013; 14: 272.
[84]
Bhargava P, Cassard S, Steele SU, et al. The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: Study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. Contemp Clin Trials 2014; 39(2): 288-93.
[85]
Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006; 13(7): 700-22.
[86]
Capriotti T, Noel J, Brissenden S. Multiple sclerosis: An update for home healthcare clinicians. Home Health Now 2018; 36(3): 169-80.
[87]
Gignoux L. Organization of healthcare in multiple sclerosis. Rev Neurol (Paris) 2018; 174(6): 471-4.
[88]
Koduah P, Paul F, Dörr JM. Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases. EPMA J 2017; 8(4): 313-25.
